Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.
about
Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewPrevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative reviewCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaEvaluation of the Xpert Carba-R (Cepheid) Assay Using Contrived Bronchial Specimens from Patients with Suspicion of Ventilator-Associated Pneumonia for the Detection of Prevalent CarbapenemasesAccuracy and generalizability of using automated methods for identifying adverse events from electronic health record data: a validation study protocol.Animal models of hospital-acquired pneumonia: current practices and future perspectivesIncidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis.A translational approach to ventilator associated pneumonia.Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogensThe impact of antimicrobial resistance and aging in VAP outcomes: experience from a large tertiary care centerImproving patient safety by optimizing the use of nursing human resources.Mechanisms of antimicrobial resistance in Gram-negative bacilli.Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study.Raman spectroscopic identification of Mycobacterium tuberculosis.SYSTEM-WIDE MAPPING OF ACTIVATED CIRCUITRY IN EXPERIMENTAL SYSTEMIC INFLAMMATORY RESPONSE SYNDROME.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Targeting bacterial biofilms via surface engineering of gold nanoparticlesTHE GLYCOCALYX AND TRAUMA: A REVIEW.AMP-activated protein kinase and Glycogen Synthase Kinase 3β modulate the severity of sepsis-induced lung injury.Is HELICS the Right Way? Lack of Chest Radiography Limits Ventilator-Associated Pneumonia Surveillance in Wales.Theory and strategy for Pneumococcal vaccines in the elderly.A more clinically relevant model of ventilator-associated pneumonia?Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy.Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?Incidence and potential risk factors for hospital-acquired pneumonia in an emergency department of surgery.In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.Modeling risk for developing drug resistant bacterial infections in an MDR-naive critically ill population.Association between pathogens from tracheal aspirate and oral biofilm of patients on mechanical ventilation.An update on the pharmacotherapeutic management of lower respiratory tract infections.Pathogenic Link Between Postextubation Pneumonia and Ventilator-Associated Pneumonia: An Experimental Study.Gene expression profile analysis of ventilator-associated pneumonia.The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
P2860
Q27013824-48685AB3-8668-46A5-AA3C-279A9B5A9E99Q28069165-31E26366-BFC0-4CCF-AA81-CF4F8B61CA99Q28071882-F1F2EECA-FD2D-4B91-80B3-C724CA5A5527Q28085517-9952741E-17BA-43F3-8195-82EE3C580DA5Q28354047-F1C9B143-E4AD-45BB-A6D4-09D9C94A1199Q31162597-DBF7F692-E008-4172-80F7-37F2F94CFFA6Q33575296-D2A83091-5015-4CD3-A0A7-057ADE93B1F9Q33869984-12FB2894-D293-4648-9657-38D8EBA0D95CQ33985790-DE914F33-921D-42F3-A4C4-2D3A0282C920Q34417616-AF5D3A6C-273C-4C1C-BB76-2F12792D188DQ34433342-6E7205E3-5064-4394-8535-1F612406EBECQ34677611-4978372C-A224-49DB-8B03-2A4A3EF6827EQ35048029-98A28259-3F15-410D-BCEA-AAA29FD27D62Q35108495-CDC2B9BD-7BAD-4342-A985-A0AA809653B5Q35737721-A48D9C9F-5075-4F57-AAF4-D9D44C0DF782Q35935319-77C470F2-AC88-4C2D-8C38-0CCA5BDAAC38Q36023350-268EB3D0-D4B3-4763-BC1A-C921F9E1A209Q36156216-DDDB4C2E-5B49-4322-A8FF-5C9C4AD72BB0Q36470840-7AA701E8-B283-4480-88F1-048FD2997FB7Q36517624-E35357F1-76D0-43AD-A544-21C7C754767FQ36566697-B6A8715F-3FC7-4565-A0F5-6456D34FA368Q36689288-52BFEC2C-593C-4543-AE9F-CA4DF6A46C37Q36757995-996CD232-5B45-4EDB-9F1B-91258AB6DC54Q37184373-5F8F3216-B21F-44D4-B2B7-DEC1F1FD2BE1Q37309215-89373E75-671A-4655-AA44-72D2A688C4B2Q37719065-4BE878D7-AF03-4CF1-BA01-A98B360D95BCQ38174871-DCF3B62F-D658-4AF3-B9B5-EB3FA734FA53Q38468392-F446EE2F-30D7-4ECF-8F7A-71CC2752F9A8Q38652103-1FEF5C6F-1598-457F-AFE0-D5EE7FA3BBE5Q38783043-FC944C1C-99BD-4C07-BE7E-6CE2DC27268EQ38835029-BD6FB783-0426-4085-8C4B-8970004455A3Q39198890-7A5C5A0D-D301-4201-97FC-1D4CE5311EF6Q39674263-B2999D44-4025-44C3-8563-739C04FCD92BQ40117928-D422A644-309A-40F3-98CE-513AA473FD23Q40181657-0AE48CDE-5EF5-4B65-8B80-35F0A5C98743Q40222424-4881B880-D72A-4899-9786-5E48FEC9F89EQ40324107-3255FD0B-3E47-4BB8-8D8E-98FF9ACABD82Q40439781-8EC800B4-DEAE-440A-96DD-FF169EE2C5DCQ40591899-DAB0B683-95DB-463D-BF2A-31A68C6885A2Q40913492-C69844A9-C803-40E1-B97F-018E1D87DAF6
P2860
Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hospital-acquired pneumonia an ...... n epidemiology and management.
@en
type
label
Hospital-acquired pneumonia an ...... n epidemiology and management.
@en
prefLabel
Hospital-acquired pneumonia an ...... n epidemiology and management.
@en
P2093
P1476
Hospital-acquired pneumonia an ...... n epidemiology and management.
@en
P2093
Antoine Andremont
François Barbier
Lila Bouadma
Michel Wolff
P304
P356
10.1097/MCP.0B013E32835F27BE
P577
2013-05-01T00:00:00Z